keyword
MENU ▼
Read by QxMD icon Read
search

Advanced nsclc

keyword
https://www.readbyqxmd.com/read/28645631/outcomes-of-first-generation-egfr-tkis-against-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations-a-post-hoc-analysis-of-the-be-positive-study
#1
Sara Pilotto, Antonio Rossi, Tiziana Vavalà, Alessandro Follador, Marcello Tiseo, Domenico Galetta, Alessandro Morabito, Massimo Di Maio, Olga Martelli, Orazio Caffo, Pier Luigi Piovano, Diego Cortinovis, Nicoletta Zilembo, Clelia Casartelli, Giuseppe Luigi Banna, Antonio Ardizzoia, Maria Luisa Barzelloni, Alessandra Bearz, Giovenzio Genestreti, Claudia Mucciarini, Virginio Filipazzi, Jessica Menis, Elisa Rizzo, Fausto Barbieri, Erika Rijavec, Fabiana Cecere, Gianluca Spitaleri, Emilio Bria, Silvia Novello
BACKGROUND: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a "real-life" Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations...
June 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28644546/-18-f-fluoromisonidazole-uptake-in-advanced-stage-non-small-cell-lung-cancer-a-voxel-by-voxel-pet-kinetics-study
#2
Daniel R McGowan, Ruth E Macpherson, Sara L Hackett, Dan Liu, Fergus V Gleeson, W Gillies McKenna, Geoff S Higgins, John D Fenwick
PURPOSE: To determine the relative abilities of compartment models to describe time-courses of 18F-fluoromisonidazole (FMISO) uptake in tumor voxels of patients with non-small cell lung cancer (NSCLC) imaged using dynamic positron emission tomography. Also to use fits of the best-performing model to investigate changes in fitted rate-constants with distance from the tumor edge. METHODS: Reversible and irreversible two- and three-tissue compartment models were fitted to 24,662 individual voxel time activity curves (TACs) obtained from tumors in 9 patients, each imaged twice...
June 23, 2017: Medical Physics
https://www.readbyqxmd.com/read/28643733/a-prospective-randomized-controlled-study-of-cisplatin-versus-carboplatin-based-regimen-in-advanced-squamous-nonsmall-cell-lung-cancer
#3
Amr Shafik Saad, Ramy R Ghali, May Ahmed Shawki
BACKGROUND: The use of cisplatin (Cis) versus carboplatin (Carb) in the treatment of advanced nonsmall cell lung cancer (NSCLC) is controversial. The aim of the study was to compare the safety and efficacy of Cis versus Carb in squamous NSCLC. PATIENTS AND METHODS: A prospective, randomized, controlled, open-label study was conducted on advanced squamous NSCLC patients who were randomly assigned to receive Cis (40 mg/m 2 [day 1 and day 8]) or Carb (area under the curve = 5 [day 1]) combined with gemcitabine [Gem] (1000 mg/m 2 [day 1 and day 8]) of a 3-week schedule for six cycles...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28643244/durvalumab-first-global-approval
#4
Yahiya Y Syed
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy...
June 22, 2017: Drugs
https://www.readbyqxmd.com/read/28641702/-prospect-and-current-situation-of-immune-checkpoint-inhibitors-%C3%A2-in-first-line-treatment-in-advanced-non-small-cell-lung-cancer-patients
#5
Haiyang Wang, Xiaoqing Yu, Yun Fan
With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and improves the curative effect. A series of randomized phase III trials are ongoing. In this review, we discuss the prospect and current situation of immune checkpoint inhibitors in first-line treatment in advanced NSCLC patients...
June 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28640869/development-of-an-automated-size-based-filtration-system-for-isolation-of-circulating-tumor-cells-in-lung-cancer-patients
#6
Satomi Yagi, Yasuhiro Koh, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Katsuya Endo, Seita Nakamura, Masayuki Higuchi, Hisashige Kanbara, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Circulating tumor cells (CTCs), defined as tumor cells circulating in the peripheral blood of patients with solid tumors, are relatively rare. Diagnosis using CTCs is expected to help in the decision-making for precision cancer medicine. We have developed an automated microcavity array (MCA) system to detect CTCs based on the differences in size and deformability between tumor cells and normal blood cells. Herein, we evaluated the system using blood samples from non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) patients...
2017: PloS One
https://www.readbyqxmd.com/read/28640540/the-effects-of-advanced-age-and-serum-%C3%AE-1-acid-glycoprotein-on-docetaxel-unbound-exposure-and-dose-limiting-toxicity-in-cancer-patients
#7
Hirotsugu Kenmotsu, Chiyo K Imamura, Akira Ono, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Tetsuhiko Taira, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Yusuke Tanigawara
AIM: α1 -Acid glycoprotein (AAG), which is a major binding protein of docetaxel, is considered to be a determinant for docetaxel pharmacokinetics. However, there are no reports about the impact of serum AAG on pharmacokinetics and pharmacodynamics in elderly patients treated with docetaxel. The aim of this prospective study was to elucidate the effects of advanced age and serum AAG on docetaxel unbound exposure and neutropenia, dose-limiting toxicity, in cancer patients. METHODS: Docetaxel was administered at 60 mg/m(2) to 51 patients with non-small cell lung cancer, 17 of whom were ≥ 75 years of age...
June 22, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28637018/the-efficacy-of-anti-pd-1-pd-l1-therapy-and-its-comparison-with-egfr-tkis-for-advanced-non-small-cell-lung-cancer
#8
REVIEW
Zhixin Sheng, Xu Zhu, Yanhua Sun, Yanxia Zhang
PURPOSE: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: The Cochrane Controlled Trial Register, Embase, Medline, and the Science Citation Index were searched for prospective published reports of atezolizumab, pembrolizumab, nivolumab in previously treated patients with advanced NSCLC. RESULTS: Finally, we identified 14 prospective published reports including four trials of atezolizumab covering 542 subjects, three trials of pembrolizumab covering 1566 subjects, seven trials of nivolumab covering 1678 subjects...
June 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28634901/changes-in-plasma-mir-9-mir-16-mir-205-and-mir-486-levels-after-non-small-cell-lung-cancer-resection
#9
Maria Sromek, Maciej Glogowski, Magdalena Chechlinska, Mariusz Kulinczak, Lukasz Szafron, Klara Zakrzewska, Joanna Owczarek, Piotr Wisniewski, Robert Wlodarczyk, Lukasz Talarek, Maciej Turski, Jan Konrad Siwicki
PURPOSE: The majority of non-small cell lung cancer (NSCLC) patients presents with an advanced-stage disease and, consequently, exhibits a poor overall survival rate. We aimed to assess changes in plasma miR-9, miR-16, miR-205 and miR-486 levels and their potential as biomarkers for the diagnosis and monitoring of NSCLC patients. METHODS: Plasma was collected from 50 healthy donors and from NSCLC patients before surgery (n = 61), 1 month after surgery (n = 37) and 1 year after surgery (n = 14)...
June 20, 2017: Cellular Oncology (Dordrecht)
https://www.readbyqxmd.com/read/28633480/a-prospective-examination-of-circulating-tumor-cell-profiles-in-non-small-cell-lung-cancer-molecular-subgroups
#10
C R Lindsay, V Faugeroux, S Michiels, E Pailler, F Facchinetti, D Ou, M V Bluthgen, C Pannet, M Ngo-Camus, G Bescher, C Caramella, F Billiot, J Remon, D Planchard, J-C Soria, B Besse, F Farace
Background: We report the first study examining the clinical, numerical and biological properties of circulating tumor cells (CTCs) according to molecular subtypes of non-small cell lung cancer (NSCLC). Patients and Methods: 125 patients with treatment-naïve stage IIIb-IV NSCLC were prospectively recruited for CellSearch analysis. Anti-vimentin antibody was included for examination of CTCs to assess their mesenchymal character. Associations of total CTCs and vimentin-positive (vim +) CTCs with clinical characteristics, tumor genotype and survival were assessed...
June 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28632731/cd47-overexpression-is-associated-with-decreased-neutrophil-apoptosis-phagocytosis-and-poor-prognosis-in-non-small-cell-lung-cancer-patients
#11
Lourdes Barrera, Edgar Montes-Servín, Juan-Manuel Hernandez-Martinez, María de Los Ángeles García-Vicente, Elizabeth Montes-Servín, Marytere Herrera-Martínez, José C Crispín, José Rafael Borbolla-Escoboza, Oscar Arrieta
BACKGROUND: Non-small-cell lung cancer (NSCLC) patients often exhibit neutrophilia, which has been associated with poor clinical outcomes. However, the mechanisms that lead to neutrophilia have not been fully established. CD47 is an antiphagocytic molecule that promotes neutrophil recruitment. METHODS: Blood was collected from 50 treatment-naive patients with advanced NSCLC and from 25 healthy subjects. The frequency of CD66b(+) cells and the expression of CD47 were determined by flow cytometry...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28631135/long-term-clinical-benefit-from-salvage-egfr-tyrosine-kinase-inhibitors-in-advanced-non-small-cell-lung-cancer-patients-with-egfr-wild-type-tumors
#12
F Koinis, A Voutsina, A Kalikaki, A Koutsopoulos, E Lagoudaki, E Tsakalaki, E K Dermitzaki, E Kontopodis, A G Pallis, V Georgoulias, A Kotsakis
BACKGROUND: Erlotinib has been approved for the management of NSCLC patients after failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is clearly associated with the presence of EGFR mutations, there is a subset of patients with EGFR wild-type (EGFRwt) tumors who impressively respond. PATIENTS AND METHODS: Patients with EGFRwt NSCLC who received salvage (≥2nd line) treatment with erlotinib for a prolonged period (>6 months), were sought from the database of the Hellenic Oncology Research Group...
June 19, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28630876/a-dosimetric-comparison-of-dose-escalation-with-simultaneous-integrated-boost-for-locally-advanced-non-small-cell-lung-cancer
#13
Wenjuan Yang, Biao Zeng, Yanfang Qiu, Jianfeng Tan, Shilei Xu, Yilong Cai, Yujuan Zhou, Zhigang Liu, Junming Luo, Hui Wang
BACKGROUND: Many studies have demonstrated that a higher radiotherapy dose is associated with improved outcomes in non-small-cell lung cancer (NSCLC). We performed a dosimetric planning study to assess the dosimetric feasibility of intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost (SIB) in locally advanced NSCLC. METHODS: We enrolled twenty patients. Five different dose plans were generated for each patient. All plans were prescribed a dose of 60 Gy to the planning tumor volume (PTV)...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28629896/randomized-phase-ii-study-of-preoperative-chemoradiotherapy-panitumumab-followed-by-consolidation-chemotherapy-in-potentially-operable-locally-advanced-stage-iiia-n2-non-small-cell-lung-cancer-nrg-oncology-rtog-0839
#14
Martin J Edelman, Chen Hu, Quynh-Thu Le, Jessica S Donington, Warren D D'Souza, Adam P Dicker, Billy W Loo, Elizabeth M Gore, Gregory M M Videtic, Nathaniel R Evans, Joseph W Leach, Maximilian Diehn, Steven J Feigenberg, Yuhchyau Chen, Rebecca Paulus, Jeffrey D Bradley
INTRODUCTION: Multimodality therapy has curative potential in locally advanced non-small cell lung cancer (LASCLC). Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology RTOG 0229 demonstrated the feasibility and efficacy of combining full dose radiation (61.2Gy) with chemotherapy followed by resection and chemotherapy. Based upon that experience and evidence that epidermal growth factor receptor (EGFR) antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in LANSCLC with a primary endpoint of MNS...
June 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28629197/reply-to-the-letter-to-the-editor-by-c-nicolazzo-et-al-circulating-cell-free-dna-and-circulating-tumor-cells-as-prognostic-and-predictive-biomarkers-in-advanced-non-small-cell-lung-cancer-patients-treated-with-first-line-chemotherapy
#15
https://www.readbyqxmd.com/read/28628916/comprehensive-biomarker-analyses-in-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-prospectively-treated-with-the-polo-like-kinase-1-inhibitor-bi2536
#16
Frank Breitenbuecher, Joachim von Pawel, Martin Sebastian, Cornelius Kortsik, Saskia Ting, Stefan Kasper, Jeremias Wohlschläger, Karl Worm, Alicia Morresi-Hauf, Arno Schad, Daniela Westerwick, Beatrice Wehler, Martin Werner, Gerd Munzert, Birgit Gaschler-Markefski, Kurt W Schmid, Martin Schuler
No abstract text is available yet for this article.
June 20, 2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/28627767/clinical-significance-of-post-progression-survival-in-lung-cancer
#17
REVIEW
Hisao Imai, Kyoichi Kaira, Koichi Minato
Progression-free survival (PFS) and overall survival (OS) are two common endpoints in cancer trials. OS is usually preferred, because it is reliable, precise, meaningful, and can easily be documented. However, subsequent lines of therapy might confound the effects of first-line treatment on OS. Whether PFS or OS is the more appropriate endpoint in clinical trials of metastatic cancer remains controversial. Previous reports on lung cancer have shown that an increase in PFS does not necessarily result in an increase in OS; however, post-progression survival (PPS) is strongly associated with OS after early-line treatment...
June 19, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28625771/comparison-of-plasma-to-tissue-dna-mutations-in-surgical-patients-with-non-small-cell-lung-cancer
#18
Kezhong Chen, Jingbo Zhang, Tian Guan, Fan Yang, Feng Lou, Wei Chen, Mingyu Zhao, Jay Zhang, Siyi Chen, Jun Wang
OBJECTIVE: Noninvasive liquid biopsies of circulating tumor DNA (ctDNA) can be used to assess non-small cell lung cancer (NSCLC), but previous work focused on patients with advanced-stage cancer. Thus, we evaluated the feasibility and their potential clinical application of circulating tumor DNA approached for surgical patients with NSCLC. METHOD: Consecutive patients with suspected lung cancer who underwent curative-intent lung resection were enrolled prospectively in this study...
May 24, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28625654/line-1-hypomethylation-is-associated-to-specific-clinico-pathological-features-in-stage-i-non-small-cell-lung-cancer
#19
Andrea Imperatori, Nora Sahnane, Nicola Rotolo, Francesca Franzi, Elisa Nardecchia, Laura Libera, Chiara Romualdi, Maria Cattoni, Fausto Sessa, Lorenzo Dominioni, Daniela Furlan
OBJECTIVES: We hypothesize that selected genetic and/or epigenetic changes associated with advanced tumours may help identifying early non-small cell lung cancers (NSCLCs) that recur after resection. Among epigenetic changes, long interspersed nuclear element-1 (LINE-1) hypomethylation is seen early during carcinogenesis and may act in concert with genetic alterations to cancer progression. LINE-1 hypomethylation and gene mutations frequently involved in lung cancer, were analysed to evaluate their prognostic role in resected stage I NSCLC...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28625652/symptomatic-leptomeningeal-metastasis-improvement-with-nivolumab-in-advanced-non-small-cell-lung-cancer-patient
#20
Maria Gion, Jordi Remon, Caroline Caramella, Jean-Charles Soria, Benjamin Besse
Leptomeningeal metastasis (LM) is reported in 3.8% of non-small-cell lung cancer (NSCLC) patients, more frequently in adenocarcinoma, and it correlates with poor prognosis. Data regarding the activity of immune checkpoint inhibitors in LM is lacking. We present a case report about the efficacy of nivolumab in a patient with advanced NSCLC and symptomatic LM.
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
81801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"